Ventricular Assist Device (VAD) Research Registry and Blood Sub-Study
Launched by SPECTRUM HEALTH HOSPITALS · Nov 23, 2022
Trial Information
Current as of January 21, 2025
Terminated
Keywords
ClinConnect Summary
Patients eligible for VAD are being sampled before surgery for plasma as well as peripheral blood cells. After surgery patients are being sampled again at 24 h and 7 days. Inflammatory response is being monitored on gene expression as well as cell level and on cytokine level in relation to the outcome.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject is ≥ 18 years of age
- • 2. Subject is treated with a VAD at the Butterworth Campus, Spectrum Health.
- Exclusion Criteria:
- • 1. Subject is less than 18 years of age.
- • 2. Known prisoners of the state.
- • 3. Subject is pregnant.
- • 4. Non- English speaking patients will be excluded from the blood sub-study
Trial Officials
Renzo Loyaga, MD PhD
Principal Investigator
The DeVos Cardiovascular Research Program, Frederik Meijer Heart & Vascular Institute, Corewell Health
About Spectrum Health Hospitals
Spectrum Health Hospitals is a leading healthcare provider dedicated to delivering high-quality patient care and advancing medical research through innovative clinical trials. As a part of a comprehensive health system, Spectrum Health Hospitals integrates cutting-edge technology and evidence-based practices to enhance patient outcomes and contribute to the broader medical community. With a commitment to ethical standards and patient safety, Spectrum Health Hospitals actively engages in diverse clinical research initiatives, fostering collaboration among healthcare professionals, researchers, and participants to drive advancements in treatment and therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grand Rapids, Michigan, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials